137 related articles for article (PubMed ID: 34648813)
1. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.
Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J
Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813
[TBL] [Abstract][Full Text] [Related]
2. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.
Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G
Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro.
Lin QM; Li YH; Lu XR; Wang R; Pang NH; Xu RA; Cai JP; Hu GX
Chem Res Toxicol; 2019 Aug; 32(8):1583-1590. PubMed ID: 31293154
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro.
Li YH; Lin QM; Pang NH; Zhang XD; Huang HL; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):337-344. PubMed ID: 31058459
[TBL] [Abstract][Full Text] [Related]
5. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX
Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574
[TBL] [Abstract][Full Text] [Related]
6. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
7. Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation.
Indra R; Pompach P; Martínek V; Takácsová P; Vavrová K; Heger Z; Adam V; Eckschlager T; Kopečková K; Arlt VM; Stiborová M
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295928
[TBL] [Abstract][Full Text] [Related]
8. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
9. Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions.
Ly JQ; Messick K; Qin A; Takahashi RH; Choo EF
Mol Pharm; 2017 May; 14(5):1754-1759. PubMed ID: 28345929
[TBL] [Abstract][Full Text] [Related]
10. Functional assessment of
Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX
Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648
[TBL] [Abstract][Full Text] [Related]
11. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640
[TBL] [Abstract][Full Text] [Related]
12. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
13. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro.
Cai Y; Lin Q; Jin Z; Xia F; Ye Y; Xia Y; Papadimos TJ; Wang Q; Hu G; Cai J; Chen L
Chem Res Toxicol; 2021 Jan; 34(1):103-109. PubMed ID: 33393779
[TBL] [Abstract][Full Text] [Related]
15. Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q; Ou-Yang QG; Lin QM; Lu XR; Ma YQ; Li YH; Xu RA; Lin DD; Hu GX; Cai JP
Fundam Clin Pharmacol; 2022 Feb; 36(1):150-159. PubMed ID: 33961299
[TBL] [Abstract][Full Text] [Related]
16. Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro.
Xie SL; Zhu X; Gao N; Lin Q; Chen C; Yang YJ; Cai JP; Hu GX; Xu RA
Food Chem Toxicol; 2023 Nov; 181():114101. PubMed ID: 37863381
[TBL] [Abstract][Full Text] [Related]
17. Gene Polymorphisms and Drug-Drug Interactions Determine the Metabolic Profile of Blonanserin.
Ye F; Li X; Ni J; Xu X; Luo J; Zhong Y; Wang Y; Wang S; Zhang Y; Hu G; Qian J
J Pharmacol Exp Ther; 2024 Jan; 388(1):190-200. PubMed ID: 37863485
[TBL] [Abstract][Full Text] [Related]
18. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Derks M; Fowler S; Kuhlmann O
Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
[TBL] [Abstract][Full Text] [Related]
19. Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
Motta P; Pons N; Pagliarusco S; Pellegatti M; Bonomo F
Drug Metab Dispos; 2011 Mar; 39(3):363-72. PubMed ID: 21149541
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
Towles JK; Clark RN; Wahlin MD; Uttamsingh V; Rettie AE; Jackson KD
Drug Metab Dispos; 2016 Oct; 44(10):1584-97. PubMed ID: 27450182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
